Cambridge Trust’s Regenxbio RGNX Stock Holding History

Cambridge Trust’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$7.8K	Hold	370	–	–	﹤0.01%	592
2023 Q4	$6.64K	Hold	370	–	–	﹤0.01%	607
2023 Q3	$6.09K	Hold	370	–	–	﹤0.01%	616
2023 Q2	$7.4K	Hold	370	–	–	﹤0.01%	619
2023 Q1	$7K	Hold	370	–	–	﹤0.01%	655
2022 Q4	$8K	Hold	370	–	–	﹤0.01%	663
2022 Q3	$10K	Hold	370	–	–	﹤0.01%	649
2022 Q2	$9K	Hold	370	–	–	﹤0.01%	697
2022 Q1	$12K	Hold	370	–	–	﹤0.01%	734
2021 Q4	$12K	Buy	+370	New	+$12.6K	﹤0.01%	786

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Cambridge Trust's RGNX Position: Q1 2024 in Review

Cambridge Trust held its Regenxbio (RGNX) position steady in Q1 2024 at 370 shares worth $7.8K. The position accounts for ﹤0.01% of the portfolio, ranked #592.

Cambridge Trust first reported a position in RGNX in Q4 2021 and has held it in 10 quarters since. The position peaked at $12K in Q1 2022. 188 funds tracked by Wall St. Rank hold RGNX as of Q1 2024.

Cambridge Trust held 370 shares of Regenxbio worth $7.8K as of Q1 2024.
Cambridge Trust left its Regenxbio share count unchanged in Q1 2024.
Regenxbio made up ﹤0.01% of Cambridge Trust's portfolio in Q1 2024, its #592 holding.
Cambridge Trust first reported a position in Regenxbio in Q4 2021 and has held it in 10 quarters since.
Cambridge Trust's Regenxbio position peaked at $12K in Q1 2022.
188 funds tracked by Wall St. Rank held Regenxbio as of Q1 2024.

Based on Cambridge Trust's 13F filing for Q1 2024, filed 30 May 2024.